» Articles » PMID: 19166708

Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease

Overview
Journal Am J Cardiol
Date 2009 Jan 27
PMID 19166708
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Antiplatelet therapy is an important treatment modality across the spectrum of coronary artery disease manifestations. The role of aspirin in primary prevention continues to be refined. Although monotherapy with either aspirin or clopidogrel has been validated in secondary prevention, for high-risk patients such as those with acute coronary syndromes or requiring percutaneous coronary intervention, dual antiplatelet therapy appears to be most beneficial. Questions remain about the appropriate duration of dual antiplatelet therapy, especially in patients with prior ischemic events or in those receiving first-generation drug-eluting stents, with indirect evidence suggesting longer durations are better.

Citing Articles

Ex Vivo Antiplatelet and Thrombolytic Activity of Bioactive Fractions from the New-Fangled Stem Buds of L. with Simultaneous GC-MS Examination.

Kumar S, Arif M, Kamal M, Jawaid T, Khan M, Mukhtar B Molecules. 2023; 28(9).

PMID: 37175328 PMC: 10179924. DOI: 10.3390/molecules28093918.


Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors.

Cacciari B, Crepaldi P, Cheng C, Bossi E, Spalluto G, Federico S Med Chem. 2019; 15(8):863-872.

PMID: 30734681 PMC: 6778720. DOI: 10.2174/1573406415666190208124534.


Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond).

Crescente M, Menke L, Chan M, Armstrong P, Warner T Br J Pharmacol. 2018; 176(8):988-999.

PMID: 29512148 PMC: 6451075. DOI: 10.1111/bph.14196.


Trends in Treatment and Mortality for Mesenteric Ischemia in the United States from 2000 to 2012.

Zettervall S, Lo R, Soden P, Deery S, Ultee K, Pinto D Ann Vasc Surg. 2017; 42:111-119.

PMID: 28359796 PMC: 5502755. DOI: 10.1016/j.avsg.2017.01.007.


Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.

Depta J, Lenzini P, Lanfear D, Wang T, Spertus J, Bach R Pharmacogenomics J. 2014; 15(1):20-5.

PMID: 25001880 PMC: 4287459. DOI: 10.1038/tpj.2014.28.